Male breast cancer with axillary lymph metastasis incidentally detected by 68Ga-PSMA PET/CT in a patient with prostate cancer

2020 ◽  
Author(s):  
Seval Erhamamci ◽  
Nesrin Aslan
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Male Breast Cancer ◽  
Male Breast ◽  
Axillary Lymph ◽  
Psma Pet ◽  
Pet Ct ◽  
Lymph Metastasis

Male breast cancer: Our experience

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10733-10733
Author(s):  
L. Tozzi ◽  
C. D’Addetta ◽  
M. Bisceglia ◽  
R. Murgo ◽  
G. Cilenti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Risk Factors ◽  
Male Breast Cancer ◽  
Dietary Factors ◽  
Male Breast ◽  
Axillary Lymph ◽  
Cancer History ◽  
Family Cancer History ◽  
Disease Free

10733 Background: Male breast is an uncommon disease, accounting for <1% of all malingnancies in the man. In contrast to women with breast cancer, men with breast cancer are older and have more advanced disease. Methods: Data regarding 25 male patients who underwent surgery for breast cancer in the our Istitution between January 1994 and December 2005 were analyzed. The main characteristics of these patients included: median age 64 years (range 32–87); positivity family cancer history: specific 4 pts, non-specific 3, no circumstance 18; risk factors: obesity 6 pts, gynaecomastia 4, diabetes 5, liver transplant 1. Five cases of second neoplasia were observed: 2 patient with prostate cancer, 1 synchronous colon carcinoma, 1 head and neck cancer, 1 pancreatic cancer. Results: All but one pts (with syncrhronous metastases at presentation) underwent mastectomy. Pathological characteristics included: pT1 tumors 3 pts (12%); pT2 7 pts (28%), pT3 2 (8%), pT4 13 (52 %); infiltrating ductal carcinomas in 88% of cases; axillary lymph node involvement in 12 (50%); 22 patients had estrogen- and progesterone-receptor positive tumors, 2 pts negative, 1 pts unknown. After surgery 14 pts received RT, 13 pts hormonotherapy and 16 patients adjuvant chemotherapy (7 CMF, 9 anthracyclin-based therapy). Median disease free survival was 41.5 months (range 5–116).With a median follow-up of 66 months, we observed 12 deaths (10 pts for progressive disease) and the overall survival rate was 52% (13 pts; 11 disease-free). According to the family cancer history we observed 5/7 (71%) and 7/18 (39%) deaths in positive and negative cases, respectively. Conclusions: The approach to male breast cancer patients is similar to that for female patients. Our data confirm the suspected epidemiologic risk factors such as prostate cancer, gynecomastia and dietary factors; furthermore, cases with family cancer history seems to have a worse prognosis. No significant financial relationships to disclose.

Male Breast Cancer Detected by 68Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis

2019 ◽  
Vol 17 (2) ◽  
pp. 154-156
Author(s):  
Giulia Polverari ◽  
Francesco Ceci ◽  
Letizia Calderoni ◽  
Veronica Cervati ◽  
Andrea Farolfi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Male Breast Cancer ◽  
Pelvic Lymph Node ◽  
Male Breast ◽  
Node Metastasis ◽  
Pelvic Lymph Node Metastasis ◽  
Pet Ct

Synchronous Detection of Male Breast Cancer and Prostatic Cancer in a Patient With Suspected Prostatic Carcinoma on 68Ga-PSMA PET/CT Imaging

2018 ◽  
Vol 43 (6) ◽  
pp. 431-432 ◽  
Author(s):  
Rajender Kumar ◽  
Bhagwant Rai Mittal ◽  
Anish Bhattacharya ◽  
Harmandeep Singh ◽  
Shrawan Kumar Singh
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Prostatic Cancer ◽  
Prostatic Carcinoma ◽  
Ct Imaging ◽  
Male Breast ◽  
Synchronous Detection ◽  
Psma Pet ◽  
Pet Ct

Diagnostic and Prognostic Value of 18F-FDG PET/CT in Male Breast Cancer: Results From a Bicentric Population

2016 ◽  
Vol 9 (2) ◽  
pp. 169-177 ◽  
Author(s):  
Laura Evangelista ◽  
Francesco Bertagna ◽  
Mattia Bertoli ◽  
Tigu Stela ◽  
Giorgio Saladini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Male Breast ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Diagnostic And Prognostic Value

scholarly journals A Synchronous Diagnosis of Metastatic Male Breast Cancer and Prostate Cancer

2019 ◽  
Vol 7 ◽  
pp. 232470961984723
Author(s):  
Leila Moosavi ◽  
Phyllis Kim ◽  
An Uche ◽  
Everardo Cobos
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Male Breast Cancer ◽  
Breast Cancer Diagnosis ◽  
Male Breast ◽  
Breast Mass ◽  
Medical Attention ◽  
Cancer History ◽  
History Of ◽  
The Right

In this article, we present a patient diagnosed synchronously with metastatic male breast cancer and prostate cancer. This is a 63-year-old male and recent immigrant from Nigeria, who sought medical attention for progressively worsening of shortness of breath and acute progression of a chronic right breast mass. An invasive breast carcinoma was diagnosed by the core biopsy of the right breast mass. Within 2 months of his breast cancer diagnosis, the patient also was diagnosed with prostate adenocarcinoma after being worked up for urinary retention. By presenting this patient with a synchronous diagnosis with metastatic male breast cancer and prostate cancer, history of chronic right breast mass, and gynecomastia, we speculate on possible cancer etiologies and risk factors.

scholarly journals Management and Outcomes of Male Breast Cancer in Zaria, Nigeria

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Adamu Ahmed ◽  
Yahaya Ukwenya ◽  
Adamu Abdullahi ◽  
Iliyasu Muhammad
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Advanced Disease ◽  
Radical Mastectomy ◽  
Male Breast ◽  
Tumor Diameter ◽  
Axillary Lymph ◽  
Breast Cancers ◽  
Modified Radical Mastectomy ◽  
Male Patients

Male breast cancer is an uncommon disease accounting for only 1% of all breast cancers. We present the evaluation, treatment and outcome of male patients seen with breast cancer in our institution. Male patients that had histological diagnosis of breast cancer from 2001 to 2010 were retrospectively evaluated. After evaluation patients were treated with modified radical mastectomy. Combination chemotherapy was given to patients with positive axillary lymph nodes. Radiotherapy and hormonal therapy were also employed. There were 57 male patients with breast cancer which accounted for 9% of all breast cancers seen during the study period. Their mean age was 59 ± 2.3 years. The mean tumor diameter was 13 ± 2.5 cm. Fifty three (93%) patients presented with advanced disease including 15 with distant metastasis. Four patients with stage II disease were treated with modified radical mastectomy, chemotherapy and tamoxifen. Of the 30 patients with sage III disease that had modified radical mastectomy, complete axillary clearance and tumor free margins were achieved in 25. Overall 21 (36.8%) patients were tumor free at one year. Overall 5-year survival was 22.8%. In conclusion, male patients with breast cancer present with advanced disease which is associated with poor outcome of treatment.

18F-FDG PET/CT for the evaluation of male breast cancer

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Francesco Dondi ◽  
Domenico Albano ◽  
Raffaele Giubbini ◽  
Francesco Bertagna
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Fdg Pet ◽  
Male Breast ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Diagnostic Performance of F18-FDG PET/CT in Male Breast Cancers Patients

Diagnostics ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 119
Author(s):  
Andra Piciu ◽  
Doina Piciu ◽  
Narcis Polocoser ◽  
Anita A. Kovendi ◽  
Iulia Almasan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Distant Metastases ◽  
Lymph Node Involvement ◽  
Male Breast ◽  
Axillary Lymph ◽  
Pet Ct ◽  
Node Involvement ◽  
Male Patients ◽  
Fdg Pet Ct

Introduction: F18-FDG PET/CT is the most important hybrid imaging used in the diagnostic, staging, follow-up, and treatment evaluation response in cancer patients. However, it is well-known that in breast cancer the use of F18-FDG is not included in the first line protocol of initial diagnostic, both in female and male breast cancer patients. F18-FDG PET/CT is a valuable tool to provide information on extra-axillary lymph node involvement, distant metastases, and other occult primary cancers. This study assesses F18-FDG PET/CT systemic staging in male patients with diagnosed breast cancer and determines detection rates for unsuspected distant metastases and synchronous malignancies. Methods: We analyzed a number of 170 male patients with breast cancer, seen between 2000–2020, in a tertiary center. From this group, between 2013–2020 a number of 23 patients underwent F18-FDG PET/CT. Rates of upstaging were determined for each case and the detection of other primary malignancies was analyzed. Results: Median age of male breast cancer group was 61.3 y (range, 34–85 y), most had intraductal carcinoma (82.4%) and unsuspected distant metastases, which increased patient stage to IV, observed in 27%. In 4 out 23 patients (17.4%), F18-FDG PET/CT identified synchronous cancers (2 prostate cancers, 1 thyroid and 1 colon cancer). Conclusion: F18-FDG PET/CT is a valuable tool to provide information on extra-axillary lymph node involvement, distant metastases, and other occult primary cancers. Baseline F18-FDG PET/CT has a substantial impact on the initial staging and on clinical management in male breast patients and should be considered for use in newly diagnosed patients.

scholarly journals Relation between male breast cancer and prostate cancer

1980 ◽  
Vol 42 (5) ◽  
pp. 787-790 ◽  
Author(s):  
L H Sobin ◽  
M Sherif
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Male Breast Cancer ◽  
Male Breast
Sign in / Sign up

Export Citation Format

Share Document